preliminary programme

P R E L I M I N A RY P R O G R A M M E
& Call for abstracts
4 th CONGRESS OF THE PSORIASIS
INTERNATIONAL NETWORK
PSORIASIS 2013
4-6 JULY 2013
PALAIS DES CONGRÈS – PARIS – FRANCE
FOR MORE INFORMATION PLEASE VISIT
www.pso2013.com
FONDATION
RENÉ TOURAINE
Organised by the Fondation René Touraine
An international foundation for dermatology
Email: pso2013@mci-group.com
Under the auspices of
the EADV Psoriasis Taskforce
2
4
Table of Contents
• Welcome Address . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
• Committees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
• Schedule at a glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
• Abstracts submission & Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
• General information & Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
• Registration procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
• Accommodation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
• Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
4
Key Dates to Remember
• Deadline for abstract submission
for free communications and posters: . . . . . . . . . . . . . . February 15, 2013
• Advance registration deadline . . . . . . . . . . . . . . . . . . . . March 20, 2013
• Deadline for hotel reservations . . . . . . . . . . . . . . . . . . . May 4, 2013
• Opening on-site secretariat . . . . . . . . . . . . . . . . . . . . . . July 4, 2013
4
Congress Office
• Scientific Secretariat, Registration, Accommodation, Exhibition, Sponsorship:
PSORIASIS 2013 – MCI
24 rue Chauchat – 75009 Paris – France
Tel.: 33 (0) 1 53 85 82 59 – Fax: 33 (0) 1 53 85 82 83
• Email:
-
For
For
For
For
general information: pso2013@mci-group.com
registration and accommodation: pso2013REG@mci-group.com
exhibition and sponsorship: pso2013EXH@mci-group.com
Abstract submission: pso2013ABS@mci-group.com
• website:
www.pso2013.com
3
4
Welcome address
Dear Colleagues and Friends,
On behalf of the Psoriasis International Network (PIN) of the Fondation René Touraine
represented by professor Carle Paul and professor Luigi Naldi, it is our great pleasure
to cordially invite you to participate in the 4th International Congress on Psoriasis.
Psonet, responsible for the scientific coordination of the congress, is a well established
network of psoriasis registries active in several European and Non-European countries,
with the aim of promoting the comparison and combination of long term outcome data.
This congress series is directly aimed to serve the needs of practicing dermatologists
involved in psoriasis care accross countries in outpatient services, hospital settings, and
private practice. Therefore, we have invited keynote speakers from all fields of psoriasis
research and care, to give you an update on the latest developments in diagnosis and
treatment of psoriasis, including comorbidites, and in difficult clinical scenarios that
may arise during the long-term management, with a view on psoriasis as a complex
chronic multifactorial inflammatory disease not limited to the skin. A perspective on
evidence-based and personalised care, on Public Health issues, and on the collaboration
to obtain a better safety profile of treatment options will be favoured.
Furtheromore, fields such as patient education, psoriasis in children and pregnancy,
topical treatment challenges, will be addressed in workshops which allow you to
directly interact with internationally experienced speakers.
Make sure that you don’t miss this unique opportunity to update your knowledge on
psoriasis, and take also the advantage to enjoy Paris at this wonderful time of the year!
Sincerely,
Luigi Naldi
Louis Dubertret
Carle Paul
Coordinator of the
scientific programme
President Board of Directors
Fondation René Touraine
Coordinator of the Psoriasis
International Network
4
4
Committees
SCIENTIFIC COORDINATION
GENERAL COORDINATION
PROGRAMME COMMITTEE
Luigi NALDI
On behalf of PSONET,
European network of psoriasis
registries
PIN Committee of the
Fondation René Touraine
Members of the PSONET
www.psonet.eu
Carle PAUL
President
Eugenia CAGGESE
Congress Secretary
Luigi NALDI
President Elect
Members of the Scientific
and Advisory Board
of the Psoriasis International
Network
www.psoriasis-international.org
NATIONAL COORDINATORS – PSORIASIS INTERNATIONAL NETWORK
AMMAR-KHODJA Aomar, Algeria
UBOGUI Javier, Argentina
CHOUELA Edgardo, Argentina
BRUNNER Patrick, Austria
ADASKEVICH Uladzimir, Belarus
DE LA BRASSINE Michel, Belgium
SEGAERT Sigfried, Belgium
DIEZ DE MEDINA Juan Carlos, Bolivia
AZULAY Luna, Brazil
SANTAMARIA Jesus, Brazil
TAKAHASHI Maria Denise, Brazil
TSANKOV Nikolai, Bulgaria
POULIN Yves, Canada
DE LA CRUZ Claudia, Chile
VALDES Pilar, Chile
RIVEROS Tatiana, Chile
ZHENG Min, China
LEE Chih-Hung, Chinese Taipei
GONZALEZ A. Cesar, Colombia
LONDONO Angela, Colombia
VARGAS Miryam, Colombia
ALVAREZ Laura, Costa Rica
CEOVIC Romana, Croatia
BLANCO G. Orestes, Cuba
PEREZ ALONSO Teresita, Cuba
RODRIGUEZ Roxana, Cuba
HERCOGOVA Jana, Czech Rep.
GNIADECKI Robert, Denmark
ESPINAL Alexandra, Dominican Rep.
URAGA Enrique, Ecuador
LOAYAZA Enrique, Ecuador
BRIONES Maria Cecilia, Ecuador
ELGAMAL Emad, Egypt
QUINTANILLA Elena, El Salvador
MARTINEZ LOPEZ Jaime, El Salvador
KINGO Külli, Estonia
RANKI Annamari, Finland
BACHELEZ Hervé, France
PAUL Carle, France
CHIJAVADZE Nino, Georgia
AUGUSTIN Matthias, Germany
ANTONIOU Christina, Greece
BRAN QUINTANA Gerardo, Guatemala
RAMOS Ligia, Honduras
KEMENY Lajos, Hungary
OLAFSSON Jon Hjaltalin, Iceland
KUMAR A.S., India
WIRYADI Benny, Indonesia
ZARGARI Omid, Iran
DAVID Michael, Israel
PAVLOVSKY Lev, Israel
NALDI Luigi, Italy
NAKAGAWA Hidemi, Japan
MALEK M. Abdul, Jordan
YOUN Jai II, Korea
AL-MUTAIRI Nawaf, Kuwait
RUBINS Andris, Latvia
KIBBI Abdul-Ghani, Lebanon
VALIUKEVICIENE Skaidra, Lithuania
DUWEB Gamal A., Lybia
MANASIEVSKA Emilija, Macedonia
SIEW ENG Choon, Malaysia
CHOONG CHOR Chang, Malaysia
BOFFA Michael, Malta
LEON Gladys, Mexico
NEDELCIUC Boris, Moldova
BENCHIKHI Hakima, Morocco
SPULS Phyllis, Netherlands
NEIRA Jorge, Nicaragua
ONUNU Abel, Nigeria
KROGSTAD Anne-Lene, Norway
MASHAL Riad, Palestine
ALVARENGA DE M. Victoria, Paraguay
GUZMAN FAWCETT Antonio, Paraguay
CASTRO VARGAS Evelyn, Peru
DEL SOLAR Manuel, Peru
FREZ Maria Lorna, Philippines
SZEPIETOWSKI Jacek, Poland
FIGUEIREDO Américo, Portugal
TIPLICA George-Sorin, Romania
POTEKAEV Nikolay, Russia
BUKHARI Iqbal A., Saudi Arabia
LY Fatimata, Senegal
MEDENICA Ljiljana, Serbia
THENG Colin, Singapore
URBANCEK Slavomir, Slovakia
MILJKOVIC Jovan, Slovenia
LUNDER Tomaz, Slovenia
PUIG Luis, Spain
STAHLE Mona, Sweden
YAWALKAR Nikhil, Switzerland
HASSAN Fouz, Syria
DOSS Néjib, Tunisia
GURER Mehmet Ali, Turkey
GRIFFITHS Christopher, UK
LITUS Oleksandr, Ukraine
CARMONA Carlos, Uruguay
MACEDO Nestor, Uruguay
LEBWOHL Mark, USA
PAEZ Erika, Venezuela
CABELLO Ismery, Venezuela
ROTHE Julia, Venezuela
There will be no further announcement before the meeting. For updates, information,
registration, abstracts submission, questions, please visit the Congress website:
www.pso2013.com
5
4
Schedule at a glance
THURSDAY, JULY 4
FRIDAY, JULY 5
SATURDAY, JULY 6
–
–
9:00
9:00
WS 4
REGISTRATION
WS 5
WS 6
WS 6 bis
WS 10
WS 11
WS 12
–
–
10:00
10:00
Break
Break
–
–
11:00
11:00
IPC Meet the experts
PLENARY SESSION 3
PLENARY SESSION 2
–
–
12:00
12:00
–
13:00
SY
ABBVIE
SY
CELGENE
–
–
SY
SY
SY
SY
GENEVRIER/
IBSA
JANSSEN
PFIZER
Lilly
Break
13:00
–
Lunch break
Lunch break
14:00
14:00
–
–
15:00
PLENARY SESSION 4
PLENARY SESSION 1
WS 7
WS 8
15:00
WS 9
–
–
16:00
16:00
Break
Break
Break
–
–
17:00
WS 1
WS 2
WS 3
SY
SY
SY
MSD
PFIZER
NOVARTIS
17:00
WS13
WS14
WS15
WS16
–
–
18:00
18:00
–
–
National Coordinators Meeting
19:00
19:00
Networking Reception
–
–
20:00
20:00
■ Satellite Symposia
■ Plenary Session
There will be in each session time for questions and answers.
■ Workshop
6
4
Abstracts submission
& Programme
The DEADLINE for ABSTRACTS submission is: February 15, 2013.
Please go to the website to read the guidelines and submit your abstract:
www.pso2013.com
All abstracts must be written in English.
Selected abstracts will be presented as posters and the best scored posters will be
presented during the workshop sessions.
Submission topics:
1. Scoring and monitoring the severity of the disease
2. Psoriasis in children and pregnancy
3. Psoriasis Arthritis
4. Comorbidities in Psoriasis
5. Psychological/Social impact of psoriasis
6. Psoriasis – pathogenesis
7. Clinical guidelines and recommendations for psoriasis treatment
8. Health economics of psoriasis
9. Patient education
10. Clinical trials in psoriasis
11. Epidemiology
12. Others
Remember that ONLY electronically submitted abstracts will be considered.
7
SCIENTIFIC PROGRAMME
4
Thursday 4th July 2013
10:00-12:00
IPC Meet the experts – A case-based Learning Discussion
12:00-13:30
SY
Satellite Symposium ABBVIE
Satellite Symposium CELGENE
14:00-16:00
PS1
O001
Plenary Session 1
Welcome Lecture: The Psonet collaboration
Luigi Naldi
Chair and Discussant: Erwin Tschachler
Psoriasis management: targeting the patient
Chairs: Mehmet Ali Gürer, Julia Rothe, Patrick Brunner
O002
• Psoriasis at the origin of the patient-based medicine
Louis Dubertret
O003
• Evaluation of severity and treatment goals
Tamar Njisten
O004
• Evidence based medicine and personalized treatment
Olivier Chosidow
O005
• Patient impact on treatment choices
Uwe Gieler
16:30-18:00
WS1
Workshop 1
Clinical guidelines and recommendations for psoriasis treatment
Chairs: Nejib Doss, Colin Theng, Gladys Leon
O021
• The methodology of developing guidelines
Catherine Smith
O022
• Guidelines around the world: a critical overview
Phyllis Spuls
O023
• The implementation of guidelines: effect of health authorities,
and reimbursement bodies
Alexander Nast
O024
• Side effects of guidelines
Chris Baker
P001
ANTIBODY FORMATION TO ADALIMUMAB IN THE TREATMENT OF PSORIASIS VULGARIS IS MOST OFTEN SEEN BEFORE
24 WEEKS OF TREATMENT AND HAS GREAT INFLUENCE ON CLINICAL EFFICACY: ONE YEAR DATA IN 59 PATIENTS
S. Menting*, P. V. Lumig, A.-C. D. Vries, G.-J. Wolbink, E. D. Jong, P. Spuls, L. Lecluse
P002
CLINICAL EXPERIENCE OF USTEKINUMAB FOR THE TREATMENT OF ELDERLY PATIENTS WITH PSORIASIS
M. Hayashi, U. Yoshinori , M. Yasuda, O. Fukuchi, T. Ito, H. Saeki, H. Nakagawa
SCIENTIFIC PROGRAMME
8
P003
DETERMINANTS OF LONG-TERM DRUG SURVIVAL OF ETANERCEPT IN PATIENTS WITH PLAQUE PSORIASIS: A DAILYPRACTICE COHORT STUDY
J. Van Den Reek*, E. de Jong, P. van de Kerkhof, M. Seyger, P. van Lümig, W. Kievit
P003bis
AN INDEPENDENT PROSPECTIVE RANDOMIZED CONTROLLED TRIAL COMPARING THE EFFICACY AND COST EFFECTIVENESS OF
INFLIXIMAB AND ETANERCEPT IN ‘HIGH NEED’ PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE TYPE PSORIASIS
A. de Vries*, T. Nijsten, B. Opmeer, H. Bonnerjee, W. de Kort, B. Horvath, E. de Jong, J. van Busschbach, M. Visser, P. Spuls
16:30-18:00
WS2
Workshop 2
Complicated scenarios
Chairs: Andrew Finlay, Claudia de la Cruz, Abdul-Ghani Kibbi
O025
• Managing psoriasis in cancer patients
Myrto Trakatelli
O026
• Managing psoriasis in patients with chronic hepatitis
Van Voorhees
O027
• Managing psoriasis in HIV and immuno-compromised patients
Martine Bagot
O028
• Drug associations and interactions
Michael David
P004
THE CARDIOVASCULAR ASSESSMENT TOOL (CVAT): ASSESSING RISK FACTORS FOR CARDIOVASCULAR DISEASE IN PATIENTS
WITH MODERATE TO SEVERE PSORIASIS TREATED WITH FUMARIC ACID ESTERS
K. Reich*, K. Merten, N. Berenzen, W.-H. Boehncke
P005
PSORIASIS IS NOT ASSOCIATED WITH ATHEROSCLEROSIS AND INCIDENT CARDIOVASCULAR EVENTS: THE ROTTERDAM STUDY
E. A. Dowlatshahi*, M. Wakkee, M. Kavousi, M. Ikram, A. Hofman, O. Franco, T. Nijsten
P006
INSOMNIA IN PATIENTS WITH PSORIASIS: CONSEQUENCES AND ASSOCIATED FACTORS
B. Halioua*, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Maunoury, M.-E. Roussel, F. Dogniaux, J.-F. Stalder
16:30-18:00
WS3
Workshop 3
Looking at the future
Chairs: Carlo Pincelli, Chih-Hung Lee, Külli Kingo
O029
• Pharmacogenetics: what could we expect for the near future?
Alexander Navarini
O030
• Phenotyping and genotyping
Tsen-Fang Tsai
O031
• Personalised medicine and psoriasis
Frank Nestle
O032
• Can progression of psoriasis be prevented?
Junko Takeshita
P007
IMPAIRED NUCLEAR TRANSLOCATION OF GLUCOCORTICOID RECEPTORS: NOVEL FINDINGS FROM PSORIATIC EPIDERMAL
KERATINOCYTES
M. Zheng*, X. Man
P008
PSORIATIC SKIN MODEL PRODUCED BY THE AUTO-ASSEMBLY METHOD: EVALUATION OF NEW ALTERNATIVES
I. Gendreau*, J. Jean, R. Pouliot
P009
CHARACTERIZATION OF PSORIATIC SKIN SUBSTITUTES CULTURED IN SERUM OR SERUM-FREE CONDITION AT THE AIR-LIQUID
INTERFACE
S. Dubois Declercq*, J. Jean, L. Gauthier, A. Duque-Fernandez, M. Auger, R. Pouliot
SCIENTIFIC PROGRAMME
9
4
Friday 5th July 2013
8:30-10:00
WS4
Workshop 4
Psoriatic arthritis
Chairs: Philip Helliwell, Vito Di Lernia, Alice Gottlieb
O033
• The diagnosis of psoriatic arthritis
Philip Helliwell
O034
• Severity assessment of psoriatic arthritis
Oliver Fitzgerald
O035
• Mild arthritis: a therapeutic challenge
Piercarlo Sarzi Puttini
O036
• Clinical guidelines for the management of psoriatic arthritis
Olivier Fitzgerald
P010
THE PREDICTIVE FACTORS OF ADVERSE EVENTS IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH ANTI-TNF DRUGS
F. Atzeni *, C. Ricci , D. Ventura, R. Caporali, L. Cavagna, F. Saccardo , R. Pellerito , R. Gorla , A. Marchesoni, P. Sarzi-Puttini
P011
ELBOW ARTHRITIS AND PALMOPLANTAR PUSTULOSIS: IS IT PSORIATIC ARTHRITIS OR SAPHO SYNDROME?
A. Souissi*, I. Gharsallah, S. Ben Taazayet, L. Metoui, B. Louzir, S. Othmani
P012
APREMILAST: POOLED SAFETY ANALYSIS OF THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS IN PATIENTS WITH
PSORIATIC ARTHRITIS
G. Schett*, P. J. Mease, A. Kavanaugh, A. O. Adebajo, J. J. Gomez-Reino, J. Wollenhaupt, M. Cutolo, E. Lespessailles, K. Shah, C.
Hu, R. Stevens, C. Edwards, C. Birbara
8:30-10:00
WS5
Workshop 5
Health economics of psoriasis
Chairs: Matthias Augustin, Robert Stern, Marcus Schmitt Egenolf
O037
• Health economics: definitions
Speaker to be confirmed
O038
• The cost of psoriasis in Europe
Livio Garattini
• The cost of psoriasis in USA
April W. Amstrong
• Cost-effectiveness analysis of psoriasis management
Matthias Augustin
O039
O040
P013
QUALITY OF LIFE AND HEALTH-STATE UTILITIES IN PSORIASIS PATIENTS AT THE NATIONAL SKIN CENTRE, SINGAPORE
J. Y. Pan* and National Skin Centre
SCIENTIFIC PROGRAMME
10
8:30-10:00
WS6
Workshop 6
Patient education
Chairs: Maria Lorna Frez, Tsira Leonidze, Fatimata Ly
O041
O042
O043
O044
• The cumulative life course impairment
Andrew Finlay
• Coping – a strategic issue
Ray Jobling
• Health education: what it is all about
Dennis Linder
• Compliance in psoriasis
Peter van de Kerkhof
P014
PATIENT TRAINING FOR PSORIASIS – EVALUATION OF A STANDARDIZED PROGRAM
H. Kling, J. Jahn , M. Sticherling*
P015
PREVALENCE OF NEGATIVE FEELINGS AND MISCONCEPTIONS ABOUT PSORIASIS IN FRENCH POPULATION
B. Halioua*, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Maunoury, M.-E. Roussel, F. Dogniaux, J.-F. Stalder
8:30-10:00
WS6
Workshop 6 bis sponsored by Pfizer
The relevance of immunogenicity in the treatment of psoriasis
Chairs: Alexander Navarini, George Sorin Tiplica
O045
O046
O047
• Classification of psoriasis gene expression patterns.
Any use for predicting treatment response?
Frank Nestle
• Immunologic responses in psoriasis patients treated by biological agents.
How frequently anti-drug antibodies develop and their clinical relevance
Denis Jullien
• Immunogenicity of anti-TNF biologic therapies in rheumatologic conditions
Gert-jan Wolbink
10:30-12:30
PS2
O006
Plenary Session 2
Keynote Lecture: Health care for psoriasis in Europe: a lesson for the future
Matthias Augustin
Chair and Discussant: Caius Solovan
Psoriasis a lifelong disease
Chairs: AJ Kanwar, Aomar Ammar-Khodja, Skaidra Valiukeviciene
O007
• Maintaining treatment after clearance: the evidence
Jonathan Barker
O008
• Chronic inflammation and metabolic syndrome: a link? Pros and Cons
Sinead Langan
O009
• Comorbidities impacting treatment choice
Carle Paul
O010
• A treatment for life: what are the limits of existing therapies
Robert Stern
SCIENTIFIC PROGRAMME
11
12:30-14:30
LUNCH BREAK
12:45-14:15
SY
Satellite Symposium GENEVRIER/IBSA
JANSSEN sponsored Satellite Symposium
PFIZER sponsored Satellite Symposium
14:30-16:00
WS7
Workshop 7
Psoriasis registries
Chairs: Alexa Kimball, Roshidah Baba, Thomas Diepgen
O048
• What registries can and cannot do
Kathleen Mc Ethone
O049
• Why and how to make a registry
Arnon Cohen
O050
• Overview of pubblications from registries
Tony Ormerod
O051
• The future of registries in psoriasis
Marcus Schmitt Egenolf
P016
SERIOUS INFECTION EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY: CURRENT STATUS OF
OBSERVATIONS
C. Leonardi, D. Fiorentino, R. Kalb, M. Chevrier* and on behalf of the PSOLAR Steering Committee
P017
MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMENT AND REGISTRY STUDY:
CURRENT STATUS OF OBSERVATIONS
L. Naldi*, A. B. Gottlieb, F. Kerdel, R. Bissonnette, S. Fakharzadeh, S. Calabro, W. Langholff, M. Chevrier and on behalf of the
PSOLAR Steering Committee
P018
PSOLAR: GLOBAL UPDATE OF A MULTICENTRE, OPEN REGISTRY OF PSORIASIS PATIENTS
K. Papp*, M. Augustin, B. Strober, V. Ho, C. Binder, S. Calabro, W. Langholff, M. Chevrier and on behalf of the PSOLAR Steering Committee
14:30-16:00
WS8
Workshop 8
Psoriasis in children, pregnancy and lactation
Chairs: Romana Ceovic, Laura Alvarez-Morales, Gudula Kirtschig
O052
• Pattern presentations of psoriasis in childhood
Alur S. Kumar
O053
• Treatment options for managing moderate to severe psoriasis in childhood
Maria Salavastru
O054
• Psoriasis and pregnancy: what the impact and what the treatment
Nick Reynolds
O055
• Pregnancy occurring during systemic treatment for psoriasis: how to manage
Edgardo Chouela
P019
CHILDHOOD ONSET PSORIASIS AND ITS DURATION: ASSOCIATION WITH FUTURE CARDIOVASCULAR AND METABOLIC
COMORBIDITIES
E. Mahe*, F. Maccari, M. Lahfa, A. Beauchet, H. Barthélémy, Z. Reguiai, N. Beneton, E. Estèves, G. Chaby, M. Ruer-Mulard, H.-G.
Steiner, C. Pauwels, M. Avenel-Audran, C. Goujon-Henry, V. Descamps, E. Begon, M.-L. Sigal and GEM RESOPSO
P020
PSORIASIFROM OR PSORIASIC ACRAL DERMATITIS AMONG 43 CASES OF PEDIATRIC PSORIASIS
A. Salhi*, S. Cheddani, T. Tounsi, M. Laadjal, L. Bouregaa, M. Timsiline, F. Younsi, H. Hammadi, A. Djeridane, A. Djoudi, A.
Ammarkhodja, A. Aitbenamar , A. Djoudi
P021
CHILDHOOD PSORIASIS: A RETROSPECTIVE STUDY OF 174 CASES.
C. Castro*, J. Ubogui, L. Suar, M. Saposnik, A. Olivera, R. Chuit, P. Bonavia, D. Ibañez, R. De la Sota, R. Valdez, G. Magariños
SCIENTIFIC PROGRAMME
12
14:30-16:00
WS9
Workshop 9 sponsored by Lilly
Drugs in the pipeline
Chairs: Matilda Bylaite, Lev Pavlovsky, Jovan Miljkovic
O056
• Upcoming new biologics
Neil Shear
O057
• Biosimilars: is it all the same?
Robert Gniadecki
O058
• New small molecules, not only biologics: expected place in therapy
Kristian Reich
O059
• Issues for drug development in psoriasis
Antonio Costanzo
P022
EARLY CLINICAL RESPONSE PREDICTS SUBSEQUENT RESPONSE IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE
PSORIASIS IN A PHASE 2 TRIAL WITH IXEKIZUMAB (LY2439821)
B. Zhu, E. Edson-Heredia*, G. Cameron, W. Shen, J. S. Erickson, D. Shrom, S. Banerjee
P023
EFFICACY OF AGANIRSEN, AN INSULIN RECEPTOR SUBSTRATE-1 ANTISENSE OLIGONUCLEOTIDE, IN THE TREATMENT OF MILD
TO MODERATE PLAQUE PSORIASIS: A RANDOMISED, DOUBLE BLIND EXPLORATORY STUDY
S. Colin, B. Darné, A. Kadi, A. Ferry, M. Favier, C. Lesaffre, J.-P. Conduzorgues, S. Al-Mahmood, E. Thorin, N. Doss*
16:30-18:00
SY
MSD sponsored Scientific Satellite Symposium
PFIZER sponsored Satellite Symposium
NOVARTIS sponsored Satellite Symposium
18:00 -19:30
National Coordinators Meeting
SCIENTIFIC PROGRAMME
13
4
Saturday 6th July 2013
8:30-10:00
WS10
Workshop 10 sponsored by Lilly
Biologics
Chair: Chris Baker, Craig Leonardi, Arnon Cohen
O060
• Antagonists of TNF alpha
Jorg Prinz
O061
• Antagonists of IL12-23 and IL 23
Kim Papp
O062
• Antagonists of IL17
Craig Leonardi
O063
• Shifting and combining in the biological era
Otsuki Mamitaro
P024
PARADOXICAL PSORIASIS INDUCED BY TUMOR NECROSIS FACTOR-ALPHA: OUR EXPERIENCE
S. Pérez-Barrio*, M. L. García-Vivar, E. Galíndez, L. Blanch, J. González de Tánago, S. Gómez, J. M. Careaga
P025
EVALUATION OF THE IMPACT OF BODY WEIGHT ON THE EFFICACY OF BIOLOGIC THERAPIES FOR THE TREATMENT OF
PSORIASIS: A DOSE-RESPONSE META-ANALYSIS
J. Mandema, M. Peterson, S. Ahadieh, H. Tan, S. Krishnaswami, R. Wolk, P. Gupta*
8:30-10:00
WS11
Workshop 11
Epidemiology meets practice in psoriasis management
Chairs: Francesco Cusano, Fouz Hassan, Ignacio Garcia Doval
O064
• Lifetime incidence and mortality of psoriasis
Wayne Gulliver
O065
• Risk factors and triggers
Abrar Qureshi
O066
• Methodology of phenotyping psoriasis
Christiane Guinot
O067
• Long term outcomes in psoriasis
Alexa Kimball
P026
PATIENT REPORTED PRIORITIES FOR COMPARATIVE EFFECTIVENESS RESEARCH IN PSORIASIS
J. Takeshita*, A. W. Armstrong, K. Callis Duffin, A. D. Robertson, R. Attor, J. M. Gelfand
P027
BIOLOGIC THERAPIES IN THE TREATMENT OF PSORIASIS: THEIR ASSOCIATION WITH THE DEVELOPMENT OF SPECIFIC
INFLAMMATORY COMORBID CONDITIONS AMONG A COHORT OF THE NEWFOUNDLAND AND LABRADOR POPULATION
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald
P028
RISK OF DEVELOPING CANCER AMONG PSORIASIS PATIENTS AS COMPARED TO NON-PSORIASIS PATIENTS.
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald
SCIENTIFIC PROGRAMME
14
8:30-10:00
WS12
Workshop 12
How would I treat it?
Chairs: Giampiero Girolomoni, Benny Wiryadi, Phyllis Spuls
O068
• Psoriasis limited to the nails: how to diagnose, assess severity
and how to treat it
Andreas Katsambas
O069
• Treating itch in psoriasis
Jacek Szepietowski
O070
• Pustular and erythrodermic psoriasis: how to manage
Luis Puig
O071
• Palmoplantar pustulosis: is it psoriasis? How to treat it
Joanna Narbutt
P029
MAINTENANCE THERAPY WITH GRANULOCYTE/MONOCYTE ADSORPTION APHERESIS FOR GENERALIZED PUSTULAR
PSORIASIS
T. Fujisawa*, M. Seishima
P030
GEOGRAPHIC TONGUE OR ORAL PSORIASIS?
B. L. S. Picciani*, S. Carneiro, J. C. Avelleira, D. Azulay, J. M. N. Pinto, E. P. Dias
P031
GENERALIZED PUSTULAR PSORIASIS: CLINICAL AND GENETIC STUDY OF 21TUNISIAN CASES
S. Marrakchi*, A. Masmoudi, M. Mseddi, S. Boudaya, H. Turki
10:30-12:30
PS3
O011
Plenary Session 3
Keynote Lecture: How to assess the safety of psoriasis drugs
Hervé Bachelez
Chair and Discussant: Joel Gelfand
Specific aspects of psoriasis management
Chairs: Jesus Santamaria, Amerigo Figueiredo, Mara Maccarone
O012
O013
O014
O015
• Emergencies in psoriasis management
Esteban Dauden
• Mild psoriasis: a therapeutic challenge
Wolfram Sterry
• Psoriasis in children
Christine Bodemer
• Psoriasis arthritis
Alice Gottlieb
12:30-14:00
SY
LUNCH BREAK
Satellite Symposium LILLY
SCIENTIFIC PROGRAMME
15
14:00-16:00
PS4
O016
Plenary Session 4
Keynote Lecture: Shifting paradigm in pathophysiology of psoriasis
Thomas Luger
Chair and Discussant: Alice Gottlieb
Optimal use of conventional systemic treatment
Chairs: Omid Zargari, Nino Chijavadze, Luca Borradori
O017
• Calcineurin inhibitor
Stefano Piaserico
O018
• Methotrexate
Richard Warren
• Fumaric acid esters
Sandra Philipp
• Acitretin
Jana Hercogova
O019
O020
16:30-18:00
WS13
Workshop 13
Advancements in phototherapy
Chairs: Nikolai Tsankov, Nawaf Al-Mutairi, Iqbal A. Bukhari
O072
• NBUVB and PUVA therapy
Giovanni Leone
O073
• Home UV treatment
José Manuel Carrascosa
O074
• Excimer laser
Klaus Fritz
• Combination therapies
Piergiacomo Calzavara-Pinton
O075
P032
EFFICACY, SAFETY AND DOSAGE OF FUMARIC ACID ESTERS IN COMBINATION WITH PHOTOTHERAPY IN PATIENTS WITH
MODERATE TO SEVERE PLAQUE-TYPE PSORIASIS
K. Reich*, B. Braeu, K. Merten, W. Griemberg
P033
IS BASIC FIBROBLAST GROWTH FACTOR A MEDIATOR THROUGH WHICH ULTRAVIOLET RADIATION INDUCES FOXP3+
REGULATORY T CELLS IN PSORIASIS?
L. Chen, X. Yang, Z. Shen*
P034
COMBINED CLIMATOTHERAPY ON THE BLACK SEA COMPARED TO NARROW BAND UVB THERAPY FOR TREATMENT OF
PSORIASIS
I. Bogdanov*, N. Tsankov
SCIENTIFIC PROGRAMME
16
16:30-18:00
WS14
Workshop 14
Triggering psoriasis: recent developments in understanding mechanisms
Chairs: Enno Christophers, Erika Paes, Gamal Duweb
O076
• Biology of the Koebner phenomenon
Georg Stingl
O077
• Adipose tissue and inflammation
Paolo Gisondi
O078
• Is there any role for medications in triggering psoriasis?
Yves Poulin
O079
• Infections and psoriasis triggering: myths and facts
George Sorin Tiplica
P035
EVALUATION OF RISK FACTORS FOR BODY WEIGHT GAIN IN PSORIATIC PATIENTS ON INFLIXIMAB: A MULTICENTRE, CROSSSECTIONAL STUDY
E. Mahe*, Z. Reguiai, H. Barthelemy, N. Quiles-Tsimaratos, G. Chaby, C. Girard, E. Estève, F. Maccari, V. Descamps, J.-L. Schmutz,
E. Begon, P. Bravard, H. Maillard, T. Boyé, A. Beauchet, M.-L. Sigal
P036
“PRO-OSTEOCLASTOGENESIS MARCH” IS INDUCED BY CUTANEOUS PRO-INFLAMMATORY MEDIATORS
A. Raimondo*, F. Ayala, R. Di Caprio, S. Lembo, M. Mattii, M. Schiattarella, N. Balato, A. Balato
P037
RELATIONSHIP BETWEEN MALE-FEMALE RATIO AND BODY MASS INDEX IN PSORIASIS IN JAPAN
R. Naito*, S. Imafuku, T. Tokunaga, K. Sasamoto, M. Koga, J. Nakayama
16:30-18:00
WS15
Workshop 15
Psoriasis and global health
Chairs: Emad Elgamal, Louis Dubertret
O080
• Variations in management of psoriasis in Europe
Ignacio Garcia Doval
O081
• Why do patient stop their psoriasis treatment: the US perspective
Joel Gelfand
O082
• Managing psoriasis in patients with less resourses
Nejib Doss
O083
• Networking in psoriasis: the example of the Euro-Asian interaction
Oleksandr Litus
P038
CLINICAL CHARACTERISTICS OF PATIENTS WITH FACIAL PSORIASIS IN MALAYSIA
A. Mohd Affandi*, F. A. Alias, T. H. Adnan, R. Baba
P039
DERMATOLOGISTS’ PRACTICES AND ATTITUDES TOWARDS THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS IN
RIYADH CITY, SAUDI ARABIA
M. A. Atwa*, L. Fiala
P040
DEPRESSION BURDEN IN PSORIASIS: A MOROCCAN STUDY
H. Benhiba*, N. Guerouaz, K. Jouid, H. Syrine, K. Senouci, B. Laila, B. Hassam
SCIENTIFIC PROGRAMME
17
16:30-18:00
WS16
Workshop 16
Topical treatment challenges
Chairs: Slavomir Urbancek, Uladzimir Adaskevich, Luigi Naldi
O084
• The optimal use of anthralin
Lajos Kemeny
O085
• Difficult localization: scalp, face, genital area and flexural areas
Yoshinori Umezawa
O086
• Palmo plantar psoriasis
Min Zheng
O087
• Combination treatment
Cesar Gonzalez
P041
NARROW BAND UVB MONOTHERAPY VERSUS TOPICAL CALCIPOTRIOL OINTMENT COMBINED WITH NARROW BAND UVB
PHOTOTHERAPY FOR TREATMENT OF PSORIASIS VULGARIS
N. A. Elsherif*, I. Elmangush, S. ElDibany
18
ABSTRACTS
4
Posters presentations
P042
ANTI-TNF-ALPHA NEUTRALIZING ACTIVITY OF PATIENTS’ SERA EVALUATED WITH A NOVEL
INTERLEUKIN (IL)-8 REPORTER CELL LINE CORRELATES WITH THE CLINICAL RESPONSE
TO ANTI-TNF-ALPHA ANTIBODY
Y. Kimura*, R. S. Omori, T. Takahashi, K. Tsuchiyama, Y. Kusakari, K. Yamasaki, S. Aiba
P043
MANAGEMENT OF PLAQUE-TYPE PSORIASIS IN THE ADULT: THE ITALIAN NATIONAL CLINICAL
GUIDELINES (ED. 2013)
S. Mantarro, F. Cusano*, F. D’Angelo, E. La Corte, M. Castriota, M. Pezza, R. V. Puca, S. De Masi,
O. De Pità, C. Blandizzi, A. Mele
P044
INCREASING THE INJECTION INTERVALS OF ADALIMUMAB IN PSORIATIC PATIENTS
O. Fukuchi*, T. Ito, Y. Umezawa, H. Saeki, H. Nakagawa
P045
THE USE OF SPA IN PSORIASIS: A MOROCCAN EXPERIENCE
N. El Moussaoui*, S. Hamada, A. Abdou, N. Ismaili, L. Benzekri, M. Ait Ourhroui, K. Senouci,
B. Hassam
P046
INSUFFICIENT TETANUS VACCINATION STATUS IN PATIENTS WITH PSORIASIS AND SYSTEMIC
IMMUNOSUPPRESSION
A. Koerber*, L. Leister
P047
ONE UNUSUAL CASE OF PSORIASIS TONGUE RESISTANT TO ANTI TNF ALFA
C. Y. Sabbag*
P048
A PHASE II STUDY OF PONESIMOD IN CHRONIC PLAQUE PSORIASIS: IMPROVEMENTS
IN PATIENT-REPORTED OUTCOMES
L. Kemeny*, R. Yankova, M. Talamonti, A. Vaclavkova, M. Burcklen, G. Thomas, D. D’Ambrosio
P049
CLINICAL PHARMACOLOGY OF ANTI-IL-17 RECEPTOR ANTIBODY KHK4827 (BRODALUMAB)
IN JAPANESE HEALTHY VOLUNTEERS AND SUBJECTS WITH MODERATE TO SEVERE PSORIASIS:
A RANDOMIZED, DOSE-ESCALATION, PLACEBO-CONTROLLED STUDY
O. Nemoto*, H. Nagashima , K. Sayama, H. Kobayashi
P050
A PHASE II STUDY OF PONESIMOD, AN ORAL, SELECTIVE SPHINGOSINE 1-PHOSPHATE
RECEPTOR-1 MODULATOR, IN CHRONIC PLAQUE PSORIASIS
S. Chimenti*, P. Arenberger, S. Karpati, P.-G. Sator, A. Vaclavkova, M. Burcklen, M. Stefani,
D. D’Ambrosio
P052
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH MODERATE TO
SEVERE PSORIASIS: 16-WEEK RESULTS OF A PHASE III, RANDOMIZED, CONTROLLED TRIAL (ESTEEM 1)
K. Reich*, K. Papp, C. Leonardi, L. Kircik, S. Chimenti, C. Hu, R. Stevens, R. M. Day, C. E. Griffiths
P053
TOFACITINIB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: 24-WEEK PRELIMINARY
ANALYSIS FROM THE 56-WEEK PHASE 3 OPT RE-TREATMENT STUDY
R. Bissonnette*, P. Foley, C. E. M. Griffiths, L. Iversen, M. Kadurina, H. L. Sofen, M. D. F. Takahashi,
M. E. Bachinsky, P. Gupta, L Mallbris, J. Proulx, H. Tan, H. Valdez , R. Wolk
P054
EFFICACY OF BIOLOGICS FOR THE DIFFICULT TO TREAT PSORIATIC LESIONS
T. Ito*, H. Saeki, O. Fukuchi, Y. Umezawa, M. Hayashi, R. Yamane, H. Nakagawa
P055
MALIGNANCY EVENTS IN THE PSORIASIS LONGITUDINAL ASSESSMET AND REGISTRY STUDY:
CURRENT STATUS OF OBSERVATIONS
R. Langley, B. Strober, M. Lebwohl, V. Ho, D. Fiorentino, S. Fakharzadeh*, S. Calabro, W. Langholff,
M. Chevrier and on behalf of the PSOLAR Steering Committee
P056
EFFICACY AND SAFETY OF SYSTEMIC METHOTREXATE VERSUS ACITRETIN IN PSORIASIS PATIENTS
WITH SIGNIFICANT PALMOPLANTAR INVOLVEMENT: A PROSPECTIVE, RANDOMIZED STUDY
A. J. Kanwar*, A. Janagond
P057
EFFECT OF GRANULOCYTE AND MONOCYTE ADSORPTION APHERESIS (GCAP) FOR THE TREATMENT
OF GENERALIZED PUSTULAR PSORIASIS: RESULTS FROM MULTICENTER STUDY IN JAPAN
S. Ikeda* and G-1 Study group
P058
POWER DOPPLER ULTRASONOGRAPHY IN INTERDISCIPLINARY PRACTICE OF PATIENTS WITH PSORIASIS
J. Ubogui*on behalf of Psoriahue, M. Saposnik, E. Saturansky, M. Rosemffet, T. Cazenave, G. Citera,
C. Marchesi, L. Carmona Cuello, L. Austin, I. Villani, C. Eguillor, M. L. Garcia Pazos
ABSTRACTS
19
P059
A PASI ≥90 RESPONSE IS ASSOCIATED WITH IMPROVED PATIENT REPORTED OUTCOMES: RESULTS
FROM A PHASE 2 STUDY IN PATIENTS WITH PSORIASIS TREATED WITH IXEKIZUMAB
E. Edson-Heredia*, S. Banerjee, B. Zhu, T. Maeda-Chubachi, G. Cameron, W. Shen, K. Gordon,
C. Leonardi
P060
PATIENT REPORTED OUTCOMES AFTER 16 WEEKS TREATMENT WITH SUBCUTANEOUS IXEKIZUMAB
IN A PHASE 2 TRIAL IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
C. Zachariae, E. Edson-Heredia*, J. S. Erickson, G. Cameron, B. Zhu, R. Matheson
P061
USE OF INFLIXIMAB IN 25 LIBYAN PSORIASIS VULGARIS PATIENTS
A. Altrabulsy, A. H. Griew, E. M. Elmangoush, G. A. Duweb*
P062
ETANERCEPT THERAPY PROVIDES RAPID RELIEF OF PSORIASIS SYMPTOMS IN PATIENTS OF LATIN
AMERICA, EASTERN EUROPE, AND ASIA
L. Kemeny*, M. Amaya, P. Cetkovska, N. Rajatanavin, L. Woan-Rouh, R. Mahboob, B. Tang,
L. Marshall, E. Y. Mahgoub
P063
TREATMENT SATISFACTION AMONG PATIENTS WITH PSORIASIS WHO WERE TREATED
WITH 2 DIFFERENT DOSE REGIMENS OF ETANERCEPT: RESULTS FROM THE PRISTINE STUDY
W.-R. Lee, J.-I. Youn, P. Altmeyer, L. Mallbris, J. Fuiman, R. Pedersen, R. Boggs*
P064
STUDY DESIGN AND BASELINE CHARACTERISTICS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND
STUDY OF ADALIMUMAB VERSUS METHOTREXATE TREATMENT IN PEDIATRIC PATIENTS WITH
CHRONIC PLAQUE PSORIASIS
K. Papp*, D. Thaçi, I. Landells, K. Unnebrink, D. A. Williams
P065
BROAD BAND UVB VERSUS PAINT PUVA FOR PALMOPLANTAR PSORIASIS
A. Lozinski*, F. Pavlotsky , A. Barzilai
P066
COMBINATION THERAPY OF BIOLOGICS WITH DEAD SEA CLIMATOTHERAPY IN PSORIASIS
M. Harari*, T. Ruzickaon behalf of RIDS, the Research Institute on Skin Diseases at the Dead Sea,
A. Ingberon behalf of RIDS, Research Institute on Skin Diseases at the Dead Sea and RIDS, the Research
Institute on Skin Diseases at the Dead Sea
P067
NATURAL PHOTOTHERAPY OF PSORIASIS AT THE DEAD SEA IN JORDAN
Z. Z. Bisharat*
P068
SUBCLINICAL ATHEROSCLEROSIS, VASCULAR DYSFUNCTION AND ABNORMAL LV MYOCARDIAL
DEFORMATION IS SIMILAR BETWEEN PATIENTS WITH PSORIASIS AND NO HYPERTENSION
AND PATIENTS WITH UNTREATED HYPERTENSION
I. Ikonomidis*, M. Varoudi, E. Papadavid, K. Theodoropoulos, C. Stamou, S. Giatrakou, D. Koumaki,
I. Papadakis, G. Pavlidis, H. Triantafyllidi, M. Anastasiou-Nana, D. Rigopoulos, J. Lekakis
P069
RELATIONSHIP BETWEEN BODY MASS INDEX AND ACTIVITY OF PSORIASIS. PSO-RISK STUDY
L. Puig*, I. Belinchón, P. de la Cueva, J. M. Carrascosa, O. Baniandrés, V. García-Patos, B. Juliá,
C. Sancho, L. Cea-Calvo, F. Vanaclocha
P070
ADIPONECTIN RECEPTOR EXPRESSION IN KERATINOCYTES OF PSORIASIS PATIENTS WITH RESPECT
TO METABOLIC SYNDROME
S. Madanagobalane*, V. Sandhya, S. Anandan, S. Rao
P071
AUTOIMMUNE THYROID DISORDERS IN PATIENTS WITH PSORIASIS
Ü. Gül*, M. Gönül
P072
SUBCLINICAL ATHEROSCLEROSIS, VASCULAR DYSFUNCTION AND ABNORMAL LV MYOCARDIAL
DEFORMATION IS SIMILAR BETWEEN PATIENTS WITH PSORIASIS AND NO HYPERTENSION
AND PATIENTS WITH UNTREATED HYPERTENSION
I. Ikonomidis*, M. Varoudi, E. Papadavid, K. Theodoropoulos, C. Stamou, S. Giatrakou, D. Koumaki,
I. Papadakis, G. Pavlidis, H. Triantafyllidi, M. Anastasiou-Nana, D. Rigopoulos, J. Lekakis
P073
CARDIOVASCULAR DISEASE RISK PROFILE IN PSORIASIS PATIENTS WITH AND WITHOUT TREATMENT
RESPONSE IN THE PRISTINE STUDY
B. Kirby, U. Mrowietz, A. Szumski, H. Jones, L. Malbris*
P074
PREVALENCE OF MAJOR CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS
UNDER SYSTEMIC THERAPY IN SPAIN. PSO-RISK STUDY
F. Vanaclocha*, L. Puig, J. L. Sánchez-Carazo, R. Rivera, L. Rodríguez, V. Rocamora, B. Juliá,
C. Sancho, L. Cea-Calvo, I. Belinchón
P075
TUBERCULOSIS, AN INDEPENDENT RISK FACTOR FOR PSORIASIS, OR A BINOMIAL RELATIONSHIP?
RETROSPECTIVE CASE CONTROL STUDIES
L. Foia*, A. E Chiriac, V. Toma, F. Filip, A. Chiriac, C. Solovan
ABSTRACTS
20
P076
VITAMIN D STATUS IN PATIENTS WITH PSORIASIS AND RHEUMATOID ARTHRITIS; ASSOCIATION
WITH DISEASE ACTIVITY AND SERUM LEVEL OF TNFM. A. Atwa*, M. Balata, N. Abdelrahman, A. Hussein, H. Kareem
P077
ASSOCIATION BETWEEN THE APOLIPOPROTEIN E (APOE) GENE POLYMORPHISM, THE SERUM APOE
AND THE METABOLIC SYNDROME WITH PSORIASIS
R. Abdel Hay*, T. Leheta, N. Ragab, L. Rashed
P078
REPORT OF THE PREVALENCE OF METABOLIC SYNDROME IN CROATIAN PSORIASIS PATIENTS
G. Krnjevic Pezic*, L. Tomic Babic, R. Ceovic, K. Kostovic, E. Lazic Mosler
P079
PSORIASIS AND COMORBIDITIES IN TUNISIAN POPULATION
M. Benelkahla, L. Boussofara*, A. Aounallah, M. Ben Moussa, N. Ghariani, W. Saidi, M. Denguezli,
C. Belajouza, R. Nouira
P080
FATAL ACUTE RESPIRATORY DISTRESS COMPLICATING GENERALIZED PUSTULAR PSORIASIS
M. Laarif, L. Boussofara*, N. Ghariani , W. Saidi, A. Aounallah, M. Denguezli, C. Belajouza,
R. Nouira
P081
A NOVEL SYSTEM FOR ESTIMATING THE METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS
O. Andreevskaia*, M. De La Brassinne, O. Vanhooteghem
P082
UNDERDIAGNOSIS OF CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH PSORIASIS UNDER
SYSTEMIC THERAPY IN SPAIN. PSO-RISK STUDY
I. Belinchón*, F. Vanaclocha, R. Jiménez-Puya, R. Taberner, J. C. Ruiz-Carrascosa, J. Labandeira,
B. Juliá, C. Sancho, L. Cea-Calvo, L. Puig
P083
LIPID DISTURBANSES IN PSORIASIS PATIENTS WITH EXESSIVE BODY MASS AND OF OBESITY
E. Topychkanova*, N. Filimonkova, N. Kiselyeva
P084
PSORIASIS COMORBIDITIES: MOROCCAN EXPERIENCE
H. Boudhir*, I. Ramli , M. Maelainin, K. Senouci , B. Hassam
P085
PERIPHERAL VASCULAR DISEASE AND CORONARY DISEASE IN PATIENT WITH PSORIASIS
M. L. Galimberti*, C. L. Anselmi, W. M. Masson Juarez, A. Cagide, E. Soriano, R. L. Galimberti
P086
CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SEVERE PSORIASIS: ARE THEY BEING WELL
SCREENED AND TREATED? A REAL-WORLD SETTING STUDY
T. Torres*, R. Sales, J. P. Ferreira, C. Carvalho, C. Vasconcelos, B. da Silva, M. Selores
P087
A CASE OF SUB ACUTE THYROIDITIS IN A PATIENT ON ADALIMUMAB FOR TREATMENT
OF REFRACTORY PALMO-PLANTAR PSORIASIS
A. Chiriac*, L. Foia, A. E. Chiriac, C. Solovan
P088
PREVALENCE OF METABOLIC SYNDROME AMONG ADULT FILIPINO PSORIASIS PATIENTS
M. L. Frez*, H. Lucero, H. M. Uichanco-Bravo, M. A. F. Cagayan, S. H. Chua
P089
PSORIASIS IN A PATIENT WITH PALMOPLANTAR ECZEMA : A CHALLENGING DIAGNOSIS
S. Ben Taazayet*, K. jaber, A. souissi, S. youssef, M. R. dhaoui, N. Doss
P090
PROBLEMS OF THE PSORIASIS, ASSOCIATED WITH VIRUSES OF HERPES SIMPLEX
H. Astsaturov*, O. Syzon
P091
SHOULD WE CONSIDERER DIFFERENT TREATMENT GOALS FOR CARDIOVASCULAR RISK FACTORS
IN PATIENTS WITH PSORIASIS?
T. Torres*, R. Sales, J. P. Ferreira, C. Carvalho, C. Vasconcelos, B. da Silva, M. Selores
P092
PSORIASIS TIED TO HIGHER RISK OF DIABETES IN MOROCCAN PATIENTS
H. Benhiba*, F. El Amrani, K. Jouid, B. Hassam
P093
PSORIASIS AND CO-MORBIDITIES NEW ASPECTS
J. Shapiro*, L. Pavlovski, A. Cohen, E. Hodak, M. David
P094
PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH PSORIASIS IN A DERMATOLOGY
DEPARTMENT IN ALGIERS
H. Sahel* and R. Belaoudmou, F. Hamchaoui, F. Otsmane, B. Bouadjar
P095
PSORIASIS AND COMORBIDITIES, A STUDY OF 77 TUNISIAN PATIENTS
A. Zaouak*, R. Benmously, H. Hammami, T. Badri, S. Fenniche, I. Mokhtar
P096
CO-EXISTING OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
M. A. Muttardi*, N. A. Elsherif, A. S. Eldahumi, I. M. Elmangush
P097
SOME DATA FROM THE EPIDEMIOLOGICAL SURVEY OF PSORIASIS IN GEORGIA
N. Chijavadze*, K. Tsagareishvili
ABSTRACTS
21
P098
LOW TREATMENT SATISFACTIONS AMONG MODERATE TO SEVERE PSORIASIS PATIENTS TREATED
WITH CONVENTIONAL THERAPIES
Q. Ding, T. Fan*
P099
SOCIODEMOGRAPHIC AND CLINICAL FEATURES OF PSORIASIS PATIENTS FROM THE SOUTHERN
TURKEY
E. Alpsoy*, B. Özkesici, B. Nazlım, E. Ergün, S. Koç, A. Akman-Karaka , E. Yılmaz
P100
PSORIASIS: WHICH MODE OF INHERITANCE FOR A COMMON DISEASE?
S. Marrakchi*, A. Masmoudi, M. Mseddi, S. Boudaya, H. Turki
P101
AN EXAMINATION OF BIOLOGIC TREATMENT GROUPS OF PSORIASIS PATIENTS IN A COHORT
OF THE NEWFOUNDLAND AND LABRADOR POPULATION
W. Gulliver*, N. Gladney, K. Collins, A. Morrissey, D. MacDonald, R. Aleghehbandan, J. Dowden
P102
PSORIASIS OF EARLY AND LATE ONSET IN TUNISIAN POPULATION
N. Litaiem, K. Jaber, J. El Khalifa, W. Kaabi, S. Youssef, M. R. Dhaoui, N. Doss*
P103
PREVALENCE OF ONYCHOMYCOSIS IN PATIENTS WITH NAIL PSORIASIS
H. Boudhir*, M. Mael Ainin , I. Ramli , M. Ait Ourhroui, B. Hassam
P104
CHARACTERISTICS OF PATIENTS WITH PSORIASIS SEEN AT THE DERMATOLOGY CLINIC
OF A TERTIARY HOSPITAL IN NIGERIA:A FOUR YEAR REVIEW 2008-2012
O. A. Falodun*
P105
THE PREVALENCE AND EPIDEMIOLOGICAL CHARACTERISTICS OF PSORIASIS MORBIDITY IN LVIV
REGION, UKRAINE
I. Voznyak*, T. Svyatenko
P106
PLACE OF PSORIASIS IN DERMATOLOGY. EXPERIENCE IN THE DEPARTMENT OF DERMATOLOGY
IN TLEMCEN (WEST – ALGERIA) 1981 – 2012
O. B. Boudghene Stambouli* and Department of Dermatology CHU University Hospital of Tlemcen
(Algeria)
P107
RETROSPECTIVE STUDY ON PSORIASIS OVER A PERIOD OF 8 YEARS (2004-2010) IN ROMANIA
A. Chiriac*, A. E Chiriac, M. Moscalu, T. Pinteala, L. Foia, C. Solovan
P108
LONG-TERM EFFICACY OF JAPANESE PSORIASIS VULGARIS TREATMENTS OVER A 35-YEAR PERIOD,
1975-2010
T. Mabuchi*, E. Akasaka, T. Ota, Y. Manabe, M. Kato, N. Ikoma, A. Oka, A. Ozawa
P109
PSORIASIS: EPIDEMIOLOGICAL STUDY ON 36 CASES IN NOUAKCHOTT
K. Mariam*, A. Kane, S. Yahya, M. Ball
P110
PSORIASIS IN DERMATOLOGY PATIENTS IN PALESTINE
H. M. Arda*, M. H. Ardah
P111
CHARACTERIZATION OF THE PATIENTS FROM THE SEVERE PSORIASIS CONSULTATION
AT HERMANOS AMEIJEIRAS HOSPITAL
T. Pérez Alonso*, E. S. Martinez Matute, D. J. Hidalgo González and Hermanos Ameijeiras Hospital
P112
PSORIASIS AND METABOLIC DISEASE IN THE REGION OF TLEMCEN: CASE-CONTROL STUDY
D. B. Boumediene*, O. Boudghene stambouli
P113
EPIDEMIOLOGY OF PSORIASIS IN EGYPT .AIN SHAMS UNIVERSITY EXPERIENCE
M. H. El Sayed*, M. F. Matta
P114
ARE PSORIASIS PATIENTS PRONE TO H. PYLORI INFECTION?
H. Shmuely, N. Domniz, E. Ben-Valid , J. Yahav , E. Hodak , M. David *
P115
COST EVALUATION OF TOPICAL THERAPIES FOR PATIENTS WITH PSORIASIS IN FRANCE
F. Maunoury*, B. Halioua, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Dogniaux,
M.-E. Roussel, J.-F. Stalder
P116
SOCIOECONOMIC CHARACTERISTICS AMONG INDIVIDUALS WITH PLAQUE PSORIASIS:
DATA FROM PATIENT REGISTRY PSOLAR
A. B. Kimball, K. Gordon, D. Pariser, B. Schenkel* and on behalf of the PSOLAR Steering Committee
P117
TRIGGERING DRUG USE IN PATIENTS WITH PSORIASIS
Z. Ogretmen*, U. A kin, M. M. Hiz, S. Cevizci
P118
DO NOT HURT YOUR SKIN: KOEBNER PHENOMENON AFTER CUPPING, A TRADITIONAL METHOD
S. Yayli*, A. Yildiz Yayli
ABSTRACTS
22
P119
AN ANTIGEN-SPECIFIC THERAPY FOR PSORIASIS; PSORIASIS DUE TO DENTAL METAL ALLERGIES
T. Shimazu*, N. Ko, R. Ko
P120
SERUM PRO-INFLAMATORY CYTOKINE LEVELS TNF-A, IL12, IL22 AND IL23 IN PATIENTS WITH
PSORIASIS AND METABOLIC SYNDROME
J. Brito*, A. K. SANDOVAL, M. Fafutis, G. Villanueva, A. Alvarado
P121
ROLE OF VEGF RECEPTORS IN NORMAL AND PSORIATIC KERATINOCYTES: EVIDENCE FROM
DIFFERENT UV IRRADIATION
M. Zheng*, J. Zhu
P122
INHIBITION OF KERATINOCYTE DIFFERENTIATION BY THE SYNERGISTIC EFFECT
OF PRO-INFLAMMATORY CYTOKINES MIMICS PSORIASIS
H. Rabeony*, I. Paris, J. Garnier, C. Barrault, N. Pedretti, K. Guilloteau, G. Guillet, M. Camus,
V. Huguier, F. X. Bernard, J. C. Lecron, F. Morel
P123
PLASMA VITAMIN A AND E LEVELS AND ASSOCIATION OF THESE LEVELS WITH DISEASE ACTIVITY
IN PATIENTS WITH PSORIASIS
Ü. Gül*, F. Bakır
P124
INTERACTION BETWEEN INNATE AND ADAPTIVE IMMUNE MECHANISMS IN THE
AUTOINFLAMMATORY PATHOGENESIS OF GENERALIZED PUSTULAR PSORIASIS
A. Arakawa, S. Vollmer, P. Besgen, M. Spannagl, J. C. Prinz*
P125
SERUM PROLACTIN LEVELS IN DERMATOLOGICAL DISEASES: A CASE CONTROL STUDY.
N. A. Elsherif*, A. I. El-Sherif, S. A. El-Dibany
P126
THE POSSIBLE ROLE OF PENTRAXIN-3 AND TNF ALPHA AS INFLAMMATORY MEDIATOR
IN PSORIASIS
R. Abdel Hay*, L. Rashed
P127
DETERMINATION OF THE ASSOCIATION OF THE POLYMORPHISM 3 UTR 1188 A/C OF IL12 P40
GENE (IL12B) WITH PSORIASIS VULGAR IN PATIENTS FROM WEST OF MEXICO
J. Brito*, A. K. Sandoval , M. Fafutis, G. Villanueva, A. Alvarado
P128
UNKNOUN MICROORGANISM IN PSORIASIS PATIENTS
T. Leonidze*, A. Tavartkiladze, N. Okroscvaridze
P129
THE ROLE OF TNF-ALPHA CONVERTING ENZYME IN PSORIASIS
K. Sato*, M. Takaishi, S. Sano
P130
MOLECULAR GENETIC ANALYSIS OF HLA CLASS I AND II GENES IN SPANISH PATIENTS
WITH PSORIASIS
M. L. García-Melgares Linares*, D. Planelles Silvestre, V. Alegre de Miquel, M. Garcia Garcerá
P131
ROLE OF RAGE IN PATHOGENESIS OF PSORIASIS
A. Mezentsev*, S. Bruskin, V. Sobolev, A. Soboleva
P132
BCL2 IN MF AND PSORIASIS BEFORE AND AFTER PUVA THERAPY
A. M. Tawdy* Hani Weshay, Doaa Mahgoub
P133
CONTINUED IMPROVEMENT OF SIGNS AND SYMPTOMS IN USTEKINUMAB-TREATED PATIENTS
WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 52 RESULTS OF A PHASE 3, MULTICENTER,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
L. Puig*, A. Kavanaugh, I. B. McInnes, A. B. Gottlieb, P. Rahman, C. Ritchlin, S. Li, Y. Wang,
M. K. Doyle, A. Mendelsohn and on behalf of the PSUMMIT 1 Study Group
P134
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC
ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL (PALACE 1)
A. O. Adebajo*, A. Kavanaugh, P. J. Mease, J. J. Gomez-Reino, J. Wollenhaupt, C. Hu, R. Stevens
P135
VARIATIONS IN TREATMENT PATTERNS, DISEASE STATUS AND OUTCOMES AMONG PATIENTS
WITH PSORIATIC ARTHRITIS RECEIVING THEIR FIRST BIOLOGIC IN EUROPEAN UNION
S. Narayanan*, A. Baskett, Y. Lu, R. Hutchings
P136
FACTORS ASSOCIATED WITH UNDIAGNOSED PSA IN PSORIASIS: ANALYSES FROM THE PREPARE
PSA STUDY
H. Bachelez*, C. Paul, M. Sticherling, L. Mallbris, D. F. Alvarez, J. Fuiman, W. Li, R. Boggs
P137
DIGITAL TITANIUM – HERBST APPLIANCE AND PSORIATIC ARTHRITIS: MANDIBULAR AND CONDYLAR
GROWTH EFFECTS
U. Garagiola*, P. Cressoni, E. Del Rosso, G. Farronato
ABSTRACTS
23
P138
PSORIATIC ARTHRITIS AND TEMPOROMANDIBULAR JOINT: HOW TO DETECT THE FIRST ARTICULAR
INVOLVEMENT
U. Garagiola*, C. Bellintani, P. Cressoni, G. Farronato
P139
INFRARED THERMOGRAPHY ADDITIONAL NON-INVASIVE METHOD IN PSORIATIC ARTHRITIS
DIAGNOSIS
I. Domarkaite-Jakovleve*, V. Kucinskiene, S. Valiukeviciene, V. Veikutis
P140
CHILDHOOD PSORIASIS: A 11- YEARS RETROSPECTIVE ANALYSIS IN CROATIA
R. Ceovic*, S. Murat Susic, K. Husar, M. Skerlev, K. Kostovic
P141
MANDIBULAR CHANGES IN PSORIATIC ARTHRITIS: 3D VOLUMETRIC STUDY WITH CONE BEAM
COMPUTERIZED TOMOGRAPHY
U. Garagiola*, P. Cressoni, R. Soldo, G. Farronato
P142
EPIDEMIOLOGY AND CLINICAL STUDY OF PEDIATRIC PSORIASIS ON BLACK SKIN IN DAKAR,
SENEGAL
M. Ndiaye*, S. O. Niang, F. Ly, A. Diop, M. Diallo, B. Diatta, M. T. Dieng, A. Kane
P143
ILVEN OR LINEAR PSORIASIS? DELVING INTO MYSTERY
K. B. Patel*
P144
PSORIASIS IN A PATIENT WITH ATOPIC DISEASE – A CASE REPORT
S. Ozanic Bulic*, L. Kotrulja
P145
ANXIETY AND DEPRESSION TEMPERAMENTS IN PATIENTS WITH PSORIASIS
N. Litaiem, S. Youssef, W. Kaabi, J. El Khalifa, K. Jaber, M. R. Dhaoui, N. Doss*
P146
PSORIASIS UNCOVERED: THE RESULTS OF TWO QUANTITATIVE SURVEYS OF PSORIASIS PATIENTS
IN AUSTRALIA
C. Baker*, P. Foley, A. Braue
P147
IMPACT ON QUALITY OF LIFE IN PATIENT WITH ECZEMA VERSUS PATIENT WITH PSORIASIS
M. Korbi, L. Boussofara*, M. Maoua, H. Kalboussi, H. Aroui, A. Aounallah, N. Ghariani,
M. Denguezli, N. Mrizek, C. Belajouza, R. Nouira
P148
QUALITY OF LIFE IN PSORIASIS: AMBULATORIAL USAGE OF PDI- PSORIASIS DISABILITY INDEX
VALIDATED FOR PORTUGUESE LANGUAGE
L. Azulay-Abulafia*, J. O. Lyra da Silva
P149
PSORIASIS AND FEMALE SEXUAL DYSFUNCTION: A CASE-CONTROL STUDY
P. S. Kurizky*, G. A. Martins, J. Carneiro, L. M. H. Mota
P150
IMPACT OF PSORIASIS ON QUALITY OF LIFE, PRODUCTIVITY AND OCCUPATIONAL ACTIVITY:
ABOUT A STUDY IN CENTRAL TUNISIA
M. Benelkahla, L. Boussofara*, M. Maoua, A. Aounallah, N. Ghariani, O. Elmaalel, M. Denguezli,
N. Mrizek, C. Belajouza, R. Nouira
P151
PREVALENCE AND CHARACTERISTICS OF CYBER PSORIATIC PATIENTS
B. Halioua*, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Maunoury, M.-E. Roussel,
F. Dogniaux, J.-F. Stalder
P152
IMPACT OF DISEASE SEVERITY ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN JAPANESE
PATIENTS WITH PSORIASIS
H. Saeki*, T. Ito, O. Fukuchi, Y. Umezawa, H. Katayama, K. Tanito, A. Igarashi, T. Etoh, T. Hasegawa,
H. Nakagawa
P153
PREVALENCE AND CHARACTERISTICS OF PSORIATIC PATIENTS REPORTING FEELING OF
STIGMATIZATION
B. Halioua*, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Maunoury, M.-E. Roussel,
F. Dogniaux, J.-F. Stalder
P154
RISK FACTORS OF SEXUAL DYSFUNCTION IN PATIENTS WITH PSORIASIS
B. Halioua*, A. Motrunich, A. Maury Le Breton, A. De Fontaubert, F. Maunoury, M.-E. Roussel,
F. Dogniaux, J.-F. Stalder
P155
CORRELATION BETWEEN PASI AND DLQI IN PATIENTS WITH PSORIASIS
B. Engin*, Z. Kutlubay, U. Çelik, Ö. Ö. Calay, S. Serdaro lu, Y. Tüzün
P156
ASSESSMENTS OF QUALITY OF LIFE AND THERAPEUTIC EFFECTS BY BIOLOGICS TREATMENT
FOR PSORIASIS VULGARIS ~A COMAPARISON BETWEEN BIOLOGICS AND CICLOSPORIN
Y. Okubo*, M. Muro, K. Wakamatsu, K. Fijishiro, H. Kawakami, H. Hirano, R. Tsuboi
ABSTRACTS
24
P157
PSYCHODERMATOLOGY: EVALUATION OF PSYCHOSOCIAL FACTORS IN MODERATE-TO-SEVERE
PSORIASIS
E. Chiticariu*, M. Mirona, C. Solovan
P158
THE POSRIASIS: THE NEED FOR CLOSE COLLABORATION BETWEEN THE PATIENT AND THE PHYSICIAN
TO OPTIMIZE TREATMENT
O. B. Boudghene Stambouli* and Department of Dermatology CHU University Hospital of Tlemcen
(Algeria)
P159
RETREATMENT IN PATIENTS ACHIEVING RESPONSE AFTER RELAPSE DUE TO TREATMENT
INTERRUPTION: RESULTS FROM THE CRYSTEL STUDY
C. Griffiths, T. Luger, Y. Brault, J.-M. Germain, L. Mallbris*
P160
THE RESPONSIVENESS TO CHANGE OF THE SIMPLIFIED PSORIASIS INDEX
L. Chularojanamontri*, C. E. M. Griffiths, R. J. G. Chalmers
P161
PSORIASIS SCREENING CAMPAIGN, THE MEXICAN EXPERIENCE
M. Gómez-Flores* and Mexican Foundation of Dermatology
P162
OBJECTIVE EVALUATION OF PSORIASIS SEVERITY USING A COMPUTERIZED PASI SCORING SYSTEM
A. Mohd Affandi*, S. H. Hussein, R. Baba, H. Nugroho, E. Prakasa, M. H. Ahmad Fadzil
P163
DRAMATIC DISEASE MODIFYING EFFECT OF SINGLE USTEKINUMAB INJECTION IN PSORIASIS
AND PSA PATIENT. 2 YEARS FOLLOW UP CASE REPORT
K. Khobzey*, B. Lytvynenko, O. Litus
P164
COEXISTENCE OF PSORIASIS AND VITILIGO
N. N. Kogan*, O. Rosati, E. Chaparro, R. Veira, A. Crespo, S. Gusis
P165
EFFECTS OF GRANULOCYTE/MONOCYTE ADSORPTION APHERESIS THERAPY ON SERUM VEGF
AND ITS SOLUBLE RECEPTOR LEVELS IN PUSTULAR PSORIASIS
M. Seishima*, T. Fujisawa , Y. Mizutani, S. Suzuki, E. Fujine
P166
FACTORS INFLUENCING ACHIEVEMENT IN NAIL PSORIASIS
H. Boudhir *, F. E. Lamchahab, A. Akazane, M. Maelainine, J. Bouhllab, M. Ait Ourhroui, B. Hassam
P167
PHOTOTHERAPY ON PSORIASIS – FIVE YEARS OF OUR WORK
N. N. Kogan*, E. Chaparro, R. Veira, A. Crespo, O. Rosati, S. Gusis
P168
VARIATIONS IN TREATMENT PATTERNS AND DISEASE SEVERITY AMONG PATIENTS WITH PSORIASIS
RECEIVING THEIR FIRST BIOLOGIC IN EUROPEAN UNION
A. Franceschetti*, R. Nausedaite, S. Narayanan
P169
ESTABLISHMENT OF A NEW IN VITRO PSORIASIS MODEL FOR RNAI STUDIES
S. Bracke*, E. Desmet, M. Carretero, S. Guerrero, S. Tjabringa, J. Schalkwijk, M. Van Gele, J. Lambert
P170
RECALCITRANT GENERALIZED PUSTULAR PSORIASIS SUCCESSFULLY TREATED WITH INFILIXIMAB
A. Zaouak*, R. Benmously, H. Hammami, T. Badri, S. Fenniche, I. Mokhtar
P171
SEVER FORMS OF GERIATRIC PSORIASIS
I. Chaari*, I. Chaari, H. ChaabenE, M. Amouri, A. Masmoudi, M. Mseddi, H. Turki
P172
ERYTHRODERMIC PSORIASIS WITH RUPIOID LESIONS
Z. Topkarci*, A. Kavak, Y. Özkan, M. Yilmaz, Z. Yazici, F. B. Karahacioglu
P173
ERYTHRODERMIC PSORIASIS SUCCESSFULLY TREATED WITH ADALIMUMAB: A CASE STUDY
D. Vidal*, L. Peramiquel, R. Olivella, M. Villar, G. Petiti, A. González
P174
FOURTH-YEAR INTERIM RESULTS FROM ESPRIT, A 10-YEAR POSTMARKETING SURVEILLANCE
REGISTRY OF ADALIMUMAB FOR MODERATE TO SEVERE PSORIASIS
F. Kerdel*, D. Thaçi, M. Bereswill, D. A. Williams
P175
METHOTREXATE AND LIVER FIBROSIS – A SURVEY OF 38 PSORIATIC PATIENTS
G. Tauber*, L. Pavlovsky, M. David, K. Shor-Steinfeld, E. Hodak
P176
GEOGRAPHIC TONGUE AND FISSURED TONGUE IN 348 PATIENTS WITH PSORIASIS:
CORRELATION WITH DISEASE SEVERITY
B. L. S. Picciani*, S. Carneiro, J. C. Avelleira, D. Azulay, J. M. N. Pinto, A. L. Sampaio, E. P. Dias
P177
PSORIASIS ASSOCIATED WITH HEPATITIS C
B. Dahmani*, O. Boudghene Stambouli
P178
PROFILE OF EPIDERMAL MICROFLORA IN PSORIATIC PATIENTS
H. Astsaturov*, O. Syzon
ABSTRACTS
25
P179
PSORIASIS AND AIDS: THE CUBAN EXPERIENCE
O. A. Blanco*, D. Verdasquera, V. Capó, M. E. Figueredo, B. Mantecón, B. L. Blanco and Institute
of Tropical Medicine ¨Pedro Kourí¨, La Habana, CUBA
P180
THE RELATIONSHIP BETWEEN PSORIASIS AND TNF- G308A AND G238A POLYMORPHISMS
Z. Ogretmen*, F. Silan, M. M. Hiz, S. Atik Yalcintepe, B. Kirilmaz, O. Ozdemir
P181
ACUTE TRANSVERSE MYELITIS DURING TREATMENT FOR SEVERE PLAQUE PSORIASIS WITH ETANERCEPT:
A CASE REPORT
J. Escalas*, N. Knöpfel, C. Calles, A. Bauzà, A. Martin-Santiago
P182
“TO KILL TWO BIRDS WITH ONE STONE”: RIFAMPICIN CLEARS PSORIASIS IN QFT-POSITIVE
PATIENTS
I. Grozdev*, N. Tsankov
P183
CLINICAL AND DIAGNOSTIC SIGNS OF PSORIATIC ERYTHRODERMA
U. P. Adaskevich*
P184
IS RESTLESS LEGS SYNDROME ASSOCIATED WITH PSORIASIS?
A. Bilgiç*, N. Samanci-Karaman, A. Akman-Karaka , E. Yilmaz, E. Alpsoy
P185
IL-6 AND TNF-ALPHA POLYMORPHISMS IN PORTUGUESE PSORIATIC PATIENTS
J. P. Ferreira*, T. Torres, C. Carvalho, A. Bettencourt, B. Leal, C. Vasconcelos, P. P. Costa, M. Selores,
B. M. Silva
P186
PECULIARITIES OF THE PSORIATIC ONYCHODYSTROPHY
E. Topychkanova, N. Filimonkova*, V. Baityakov
P187
KNOWLEDGE ABOUT PSORIASIS AMONG NURSES IN NON-DERMATOLOGICAL HEALTHCARE
INSTITUTIONS
R. Petrauskiene*, T. Dimsiene, S. Valiukeviciene, J. Macijauskiene
P188
PSORIASIS RESULTING FROM PEGYLATED INTERFERON ALPHA AND RIBAVIRIN TREATMENT
OF CHRONIC HEPATITIS C
W. Kaabi, S. Youssef, N. Litaiem, J. El Khalifa, K. Jaber, M. R. Dhaoui, N. Doss*
P189
CLINICAL AND SOCIODEMOGRAPHIC FACTORS AFFECTING SCALP PSORIASIS: A COMPERATIVE
CASE-SERIES STUDY
A. Akman-Karakas*, E. Yılmaz, E. Alpsoy
P190
APOE ISOFORMS IN PATIENTS WITH PSORIASIS
J. C. P. Ferreira*, T. Torres, C. A. Carvalho, A. Bettencourt, B. Leal, C. Vasconcelos, P. P. Costa,
M. Selores, B. M. Silva
P191
STATE OF VACCINATIONS IN PSORIASIS PATIENTS
M. Sticherling*, E. Tasler-Salloum
P192
MANAGEMENT OF PSORIASIS AMONG MILITARIES: OUR EXPERIENCE IN MILITARY HOSPITAL OF TUNIS
J. El Khalifa , K. Jaber , N. Litaiem , W. Kaabi, S. Youssef , R. Dhaoui , N. Doss*
P193
METHOTREXATE AND PSORIASIS: LESS PAIN FOR MORE GAIN
J. El Khalifa, W. Kaabi, S. Youssef , N. Litaiem , K. Jaber, R. Dhaoui, N. Doss*
P194
PARADOXAL PSORIASIFORM ERUPTIONS AFTER THE ANTI-TNF ALPHA THERAPY IN EIGHT PATIENTS
S. Urbancek*, P. Kozub, M. Kuklova-Bielikova
P195
FOURNIER’S GANGRENE IN A PATIENT TREATED WITH ETANERCEPT: A REPORT OF A CASE
H. Sahel* and N Nait Saada, F Otsmane, B Bouadjar
P196
COEXISTENT PSORIASIS AND DISCOID LUPUS ERYTHEMATOSUS: A CASE REPORT
A. Souissi*, K. Jaber, S. Ben Taazayet, S. Youssef, M. R. Dhaoui, N. Doss
P197
ADALIMUMAB-INDUCED LUPUS ERYTHEMATOSUS
J. A. Pujol-Montcusí*, L. Pastor-Jane, P. Turegano, M. Simo, R. Fontova, M. Papo
P198
LEPROSY TUBERCULOID ASSOCIATED WITH PSORIASIS TREATED WITH IMMUNOBIOLOGICAL:
REPORT OF A CLINICAL CASE
E. A. F. Santos, E. B. P. Brito*, G. B. P. Brito, A. C. V. Fernades, J. Dias
Lilly, Major Corporate Partner,
welcomes delegates to the
th
4 Congress of The Psoriasis
International Network.
Lilly Satellite Symposium to be held Sat.Jul.6.2013 12:30 –2pm.
©2012, Lilly USA, LLC. ALL RIGHTS RESERVED.
lillyforbetterhealth.com
27
4
General information
& Conditions
● Welcome to Paris!
Palais
des Congrès
Roissy
Charles de Gaulle
Gare St Lazare
Gare du
Nord
Gare
de l'Est
Gare
Montparnasse
Gare
d’Austerlitz
Gare
de Lyon
Orly
● Venue & Dates
● Congress office
The 4th International Congress of Psoriasis will be
held from Thursday 4 to Saturday 6 July 2013 in the
Palais des Congrès, in Paris.
Before and after the meeting:
Paris can easily be reached by plane, train or car,
as it is located crossroad of Europe. It is served by
two international airports and a very convenient
railway system. The shuttle buses from Charles de
Gaulle or Orly airports arrive down town.
The Palais des Congrès is easily accessible: by car
(Parking Porte Maillot under the Convention Centre),
by local city bus (lines 82 - 73 - 43 - 244 PC) or by
metro (line 1) or RER (Paris Suburban Express
Metropolitan Network, line C). The station is called
“Porte Maillot”.
● Official language
Organized by an International Scientific Society,
all presentations will be given in English.
PSORIASIS 2013 – MCI
24 rue Chauchat
75009 Paris – France
Tel.: 33 (0) 1 53 85 82 59
Fax: 33 (0) 1 53 85 82 83
E-mail: pso2013@mci-group.com
Web: www.pso2013.com
On-site Secretariat: (Tentative Opening hours)
• Thursday, July 4, 2013 : 08:30am – 06:30pm
• Friday, July 5, 2013 : 07:30am – 06:00pm
• Saturday, July 6, 2013 : 08:00am – 06:30pm
The Congress documentation will be available
there for pre-registered delegates and for anyone
wishing to register on site.
28
● Badges
A name badge will be provided with your
registration documents on site (and not mailed out
prior to the congress).
As a pharmaceutical company or manufacturer,
you may want to sponsor a session within the core
programme or organize a satellite meeting.
For exhibit or sponsorship, you can contact any
time the Congress Office:
● Climate and clothing
pso2013EXH@mci-group.com
The weather in Paris in July is usually hot and sunny
with daily temperatures ranging from 20°C to 25°.
● Insurance & Liability
Night temperatures are usually mild.
● CME Credits
Continuing Medical Education credits will be
offered by Medical Academies and Scientific
Societies from all over the world. Participants may
register for CME credits in their own countries.
The Organizers will accept no liability for personal
injuries sustained by or for loss or damage to
property belonging to Congress participants, either
during or as a result of the Congress or during
all events.
Certificate of attendance will be delivered on site.
Participants are strongly recommended to seek
insurance coverage for health and accident, lost
luggage and trip cancellation.
More information will be posted on the Congress
website.
● Lunches & Break
● Currency exchange
ALL RATES given in the programme are in EUROS: €
Lunches are NOT included in the registration fees
but sandwiches and snacks can be purchased at
all times within the premises of the Palais des
Congrès.
● Electricity
Electricity used in France is 220 Volts; its
frequency is 50 Hz and the plugs have two male
contact points. Plan to bring a transformer for
your electrical or electronic equipment using
different voltage.
● Exhibition & sponsorship
A scientific and technical Showcase will be open
on Thursday afternoon, Friday and Saturday to
pharmaceutical companies, manufacturers of
materials and equipment and scientific publishers.
It will be held in the Congress Venue.
● Telephones
For international calls to France, dial the international
code followed by 33 and the correspondent’s
number without the “0”.
● Visa & Passeports
Every person entering France should be in
possession of a valid passport and/or identification
card. Some countries require a Visa.
Please contact the nearest French Embassy or
Consulate to your home for further information.
29
4
Registration procedure
All participants must be registered and are urged to register in advance. You can register by submitting
registration and payment via the Congress website: www.pso2013.com (and follow the instructions).
You can either download the registration form on PDF format and send it along with your payment to the
Congress Office OR register on line on a secure server in paying with your credit card or bank transfer.
Registration per phone will not be processed. Registrants will receive confirmation by way of an invoice
and acknowledgement letter which will be mailed and which will recall all the information given on the
registration form, including the amount of Value Added Tax (VAT) paid and all other requests. This
confirmation letter should be presented upon arrival at the Pre-registration Counter.
Until March 20, 2013
After March 20, 2013
On-site
Participants
560€
630€
710€
Students*
200€
200€
200€
Patient Association member**
Free
Free
Free
All indicate rates above include a VAT of 19,60% at current rate at the day of printing.
* Please provide certificate
** Please provide a copy of a valid membership card.
● Delegates’ registration fees include
• Admission to all congress sessions, poster
areas and technical exhibition
• Congress documents (final programme, abstracts
book, congress bag)
• Access to the Courses on Thursday, July 4,
10:00-12:00 – On-line reservation mandatory
• Networking Reception on Thursday, July 4
● Terms of payment
• The “Fondation René Touraine pour la
Dermatologie”, (domiciliée Hôpital Saint Louis,
1, avenue Claude Vellefaux, 75010 Paris) has
given mandate to MCI for the organization of
the 4th INTERNATIONAL CONGRESS ON
PSORIASIS 2013 and therefore to act and
receive the fees on its behalf.
• Payment must be sent to the Congress Office in
EUROS (€)
- by cheque payable in France to the order of
PSO 2013 - MCI
or - by Credit card : VISA, EURO/MASTER CARD
or AMEX only (NO other cards accepted)
or - by bank transfer to the order of PSO 2013 – MCI
to CREDIT LYONNAIS – Paris SDC Ouest
19, boulevard des Italiens
75002 Paris – France
Bank code: 30002 – Sort Code: 05666 – Account
N°: 0000060496L – Key: 01 – BIC: CRLYFRPP –
IBAN: FR78 3000 2056 6600 0006 0496 L01
Copy of the bank transfer must be attached to the
registration form. Do NOT forget to give the name
of the person you are paying for, on the bank
transfer order.
● Name changes / modifications
A processing fee of 30€ will be charged for changes
in registration except for name substitutions which
will be treated as new registrations.
● Cancellation policy for individual
registration & reservations
All cancellations must be notified in writing (by
mail or e-mail) to the Congress Office according to
the following conditions and reimbursement will be
processed AFTER the Congress. Requests for
refunds made after September 1, 2013 will not be
considered:
• Up to March 20, 2013: 100€ will be withheld
for administrative fee,
• Cancellations between March 21 and May 1,
2013: reimbursement of 50% of the fees paid,
• After May 1, 2013: no refund.
30
4
Accommodation
Hotel rooms at special Congress rates are being held for congress participants and their families in
various hotels of different categories in the vicinity of the Congress Venue. But there will be no shuttle
services provided by the congress between the congress hotels and the Palais des Congrès.
To make a reservation, visit the Congress website: www.pso2013.com. A PAYMENT of the FULL STAY
will be requested for all hotel reservations. It will be automatically deducted from the total amount of
your hotel bill when leaving.
● Room rates
All rates are indicated in euros, per night and per
room. Reservations must be made through the
Congress Office to guarantee the indicated rates
negotiated for the Congress. Unless otherwise
indicated, most of the rates do not include
breakfast.
Do not forget:
• If you decide to postpone your stay at the last
minute, the rooms will be kept by the hotels
according to the amount of the payment received.
• If you are delayed, think of informing the hotel.
• No reservation will be made without the
requested deposit.
For University housing, please consult the web site.
● Cancellation conditions
for hotel reservations
All cancellations must be notified in writing (by
mail or fax BUT NOT email) to the Congress
Office according to the following conditions:
• Cancellations between March 21 and May 2,
2013: 50% of the payment will be withheld
• After May 2, 2013: no refund.
★
Hotels
Type of room
Single room
Double room
H1
4
Méridien Etoile
Deluxe
239€
259€
H2
4
Concorde La Fayette
Classic
200€
220€
H3
3
Magellan
Standard
129€
153€
H4
3
Résidence Impériale
Superiors
195€
210€
H5
3
Best Western Star Champs Elysées
Classic
198€
241€
H6
3
Fertel Maillot
Standard
140€
155€
The rates are breakfast and taxes included.
31
Sponsors acknowledgements
The Organising Committee would like to thank
the following companies for their support:
MAJOR CORPORATE PARTNERS
CORPORATE PARTNER
CORPORATE SUPPORTERS
GENEVRIER/IBSA
JANSSEN
MSD
CONGRESS OFFICE
PSORIASIS 2013 – MCI
24 rue Chauchat – 75009 Paris – France
Tel.: 33 (0) 1 53 85 82 59 – Fax: 33 (0) 1 53 85 82 83
Email: pso2013@mci-group.com
website: www.pso2013.com